Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 252

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 252
---
 1,275 shares under (ii) and on February 24,          
 2025, the board of directors confirmed that the performance criteria has been met with regards to the other installment, resulting in   
 the vesting of the remaining 1,275 shares under (ii).                                                                                   |

| (2) | This includes the option to purchase 2,550 shares of Common                                                                           
 Stock, which vest in two equal installments subject to the satisfaction of certain performance criteria; on December 2, 2024, the     
 board of directors confirmed that the performance criteria had been met with regards to one installment, resulting in the vesting of  
 1,275 shares and on February 24, 2025, the board of directors confirmed that the performance criteria has been met with regards       
 to the other installment, resulting in the vesting of the remaining 1,275 shares under (ii). Mr. Patel received $75,000 in consulting 
 fees pursuant to the agreement between Mr. Patel and the Company.                                                                     |

| (3) | This includes the option to purchase 1,125 shares of Common                                                                      
 Stock granted to the non-employee director on March 25, 2024 at an exercise price of $177.00 per share; such award was forfeited 
 following the director’s resignation from the board of directors.                                                                |

| (4) | This includes the non-employee director compensation for                                                
 the director for the period of service prior to the director’s resignation from the board of directors. |

On March 4, 2025, granted to each non-executive director options to purchase up to 35,845 shares of Common Stock, with 50% subject to vesting on the twelve-month anniversary of the date of grant and the remaining 50% subject to performance-based vesting conditions. 145 PRINCIPAL STOCKHOLDERS The following table sets forth information regarding the beneficial ownership of our common stock as of May 19, 2025, by:

| ● | each person known by us to be the beneficial owner of more 
 than 5% of our outstanding shares of Common Stock;         |

| ● | each of our named executive officers and directors that beneficially 
 owns shares of our Common Stock; and                                 |

| ● | all our executive officers and directors as a group. |

Beneficial ownership is determined in accordance with the rules and regulations of the SEC, which generally provide that a person has beneficial ownership of a security if he, she